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ABSTRACT
In this study, we evaluated the mutations of Helicobacter pylori associated with resistance 
to clarithromycin and levofloxacin. Furthermore, based on the proposed interaction between 
antimicrobial resistance and pathogenicity, we correlated the mutation profiles of the strains 
with the presence of the pathogenicity gene cagA. We analyzed 80 gastric biopsy specimens 
from H. pylori-infected patients for point mutations in the 23S rRNA gene region and in the 
gyrA gene, which are related to clarithromycin and levofloxacin resistance, respectively, and 
investigated the presence of the cagA gene in these strains. We observed that in the assayed 
biopsies, 8.7% (7/80) had mutations in the 23S rRNA gene region at positions 2143 and 
2142, while 22.5% (18/80) had mutations in gyrA at codons 87 and 91. Moreover, absence 
of the CagA-EPIYA pathogenicity factor was observed in 68% (17/25) of resistant samples. 
The knowledge of the local profile of antimicrobial resistance and the complex interplay 
involving resistance and pathogenicity can contribute to an appropriate clinical approach.
KEYWORDS: Antimicrobial resistance. Point mutations. Clarithromycin. Levofloxacin. 
CagA EPIYA.
INTRODUCTION
The successful treatment of patients infected with Helicobacter pylori can aid 
in prevention of serious gastroduodenal diseases, such as gastritis, peptic ulcers, 
adenocarcinoma and MALT (Mucosa-Associated Lymphoid Tissue). According 
to the Maastricht V Consensus, therapeutic regimens for eradication of this 
microorganism involve the use of combination therapy. Triple therapy, recommended 
as a first-line empirical treatment, uses a combination of amoxicillin (AMX) and 
clarithromycin (CLA) plus a proton pump inhibitor. However, in areas of high 
clarithromycin resistance (more than 15%), quadruple therapy with bismuth is the 
recommended first-line treatment. As a rescue option, the second-line treatment is 
based on the use of levofloxacin (LVX)1.
A high failure rate of anti-H. pylori therapy is observed, primarily due to 
the acquisition of point mutations by H. pylori that results in resistance to the 
antimicrobials CLA and LVX. This mechanism of resistance is related to the frequent 
and/or inadequate use of antimicrobials, which can place selective pressure on 
resistant strains. Regarding CLA resistance, an association of CLA resistance with 
the presence of mutations in the 23S rRNA region has been described, especially 
at position 2143 (A→G) and 2142 (A→G)2. The resistance of H. pylori to LVX 
is associated with the presence of mutations in the gyrA gene, especially at codon 
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Asn87 (substitution of asparagine by lysine) and Asp91 
(substitution of aspartic acid by asparagine)3.
In addition to the resistance mechanisms developed by 
H. pylori against these antimicrobials, some studies have 
noted that the presence or absence of certain pathogenicity 
genes of bacteria and the gender and age of the patients are 
risk factors in the development of antimicrobial resistance4,5. 
There is evidence that the presence of the cagA (cytotoxin-
associated gene A) pathogenicity gene plays an important 
role in the induction of these severe gastric disorders. This is 
primarily due to the variable number of repetitive sequences 
of amino acids Glu-Pro-Ile-Tyr-Ala (EPIYA) in its 3’ region, 
where it undergoes tyrosine phosphorylation, which may 
result in modulation of the inflammatory response6.
Therefore,  some studies have proposed the 
implementation of a molecular approach for gastric 
biopsy specimens of H. pylori in clinical practice since 
H. pylori exhibits slow growth and requires specific culture 
medium, making the phenotypic approach challenging 
and slow. Furthermore, molecular methods are capable of 
detecting the molecular basis of resistance and identifying 
pathogenicity genes7,8.
Thus, in this study, we analyzed mutations in 23S rRNA 
and gyrA genes, which are related to resistance of a 
component of the first choice therapy, clarithromycin 
(CLA) and to the antimicrobial used as an alternative to 
standard therapy, levofloxacin (LVX), respectively2,3. In 
addition, we correlated this resistance with the presence 
of the pathogenicity gene cagA and with epidemiological 
factors of the patients included in the study.
MATERIAL AND METHODS
We analyzed 80 gastric biopsy specimens previously 
identified as H. pylori positive, obtained from upper 
digestive tract endoscopies of patients at the Sao Francisco 
de Paula University Hospital, in the city of Pelotas, Brazil. 
All patients provided informed consent and responded to 
a questionnaire. This study was approved by the Ethics 
Committee of the Universidade Catolica de Pelotas 
(registration Nº 658.179).
H. pylori infection was determined by histological 
analysis or by an in-house urease test and was confirmed by 
polymerase chain reaction (PCR). The histological analysis 
of the gastric biopsy was performed by Hematoxylin-
Eosin and Giemsa staining. For the in-house urease test, 
the biopsies were incubated in 1.0 mL of urea broth 
(Isofar, Brazil), prepared according to the manufacturer’s 
instructions. The DNA was extracted from the biopsies, and 
the glmM gene was PCR amplified to confirm the H. pylori 
infection, as previously described by Vianna et al.9.
The PCR-RFLP (Restriction Fragment Length 
Polymorphism) approach was used to investigate the 
mutations related to CLR resistance in the 23S rRNA 
gene at positions 1342 to 1360 and 2765 to 2745 
(complementary to the Escherichia coli homolog), which 
amplified an approximately 1,400 bp fragment. The 
fragment was digested with the restriction enzymes MboII 
and BsaI at 37 °C for 2 h and 30 min, to detect mutations 
at A2142G and A2143G, respectively, as previously 
described2. The mutations related to LVX resistance 
were explored by assessing the sequences at H. pylori 
positions 752601 to 752620 and 753182 to 753163, which 
amplified an approximately 582 bp fragment of gyrA, 
as previously described3. The sequencing equipment 
was an ABI 3500 Genetic Analyzer, Life Technologies - 
Applied Biosystems, used according to the manufacturer’s 
instructions. Sequence alignment was performed using the 
BioEdit Sequence Alignment Editor, and sequences were 
compared to the genome of H. pylori 26695 by BLAST 
analysis. 
The presence of the cagA gene was assessed by 
amplification of a variable region in the 3’ portion of the 
coding region. The reactions yielded products of 500-850 bp 
as follows: EPIYA AB, 500 bp; EPIYA-ABC, 640 bp; 
EPIYA-ABCC, 740 bp; and EPIYA-ABCCC, 850 bp, as 
previously described6,9. 
Statistical analysis was performed by using the Fisher’s 
Exact Test and the Chi-Squared Test. P values of less than 
0.05 were considered statistically significant.
RESULTS
Among the 80 samples from H. pylori positive patients 
included in the study, seven presented mutations in the 
23S rRNA region related to CLA resistance (8.7%). Of 
these, 85.7% (6/7) had mutations at position 2143, followed 
by 14.3% (1/7) at position 2142. Furthermore, in eighteen 
patients we identified mutations in the gyrA gene related to 
LVX resistance (22.5%). We observed that 83.3% (15/18) 
of the mutations in gyrA were at codon 87, while 16.7% 
(3/18) were at codon 91.
In addition, we investigated the association between 
H. pylori-positive patients with or without point mutations 
related to resistance to CLA or LVX with respect to sex, 
age, endoscopic diagnosis, previous treatment, drinking 
water source and the presence of CagA-EPIYA, as shown in 
Table 1. A statistically significant association was detected 
between mutations related to resistance with patients aged 
45 years or more (p=0.024). Moreover, the absence of the 
pathogenicity factor CagA-EPIYA was observed in 68% 
(17/25) of resistant samples.
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DISCUSSION
Although effective treatment regimens for H. pylori 
infections are available, the local antimicrobial resistance 
profile of strains should be considered. In the present study, 
8.7% (7/80) of the samples presented a mutation in the 
23S rRNA region associated with CLA resistance, similar 
to the average ratio reported by other Brazilian studies, 
which reported values ranging from 7 to 27%5.
The prolonged use of CLA in the treatment of other 
infections could be related to the selective pressure that 
results in the emergence of resistant microorganisms. The 
mutation 2143 (A→G) was detected in 85.7% (6/7) of 
samples, whereas only one strain had a mutation in the 2142 
region (A→G). The predominance of the A→G mutation at 
sites 2142 and 2143 was suggested by Nash and Inderlied10 
to be a result of the greater stability on the conformational 
change within the ribosome than mutations from A→T or 
A→C10,11. The mutation at position 2143 (A→G) of the 
23S rRNA gene has also been predominantly detected in 
other studies4,12. However, a large geographic variation 
can be observed, and an uneven distribution is possible 
even within a single country, highlighting the importance 
of characterizing the regional profiles of strains to provide 
a correct therapy13,14.
Regarding LVX, used as an alternative to conventional 
antimicrobials for the treatment of H. pylori, we detected 
the presence of mutations in the gyrA gene in 22.5% (18/80) 
of the patients and these mutations confer LVX resistance. 
These results are similar to the ones found in another study 
carried out in Brazil14. The mutations were detected at 
positions Asn87 83.3% (15/18) and Asp91 16.7% (3/18) 
in gyrA. The presence of mutations in these regions also 
has been previously reported in several countries, including 
Brazil3,8,15.
Several factors may be associated with antimicrobial 
resistance in H. pylori4. In this study, a significant 
association was detected among mutations related to 
resistance in patients older than 45 years old (p=0.024). 
The high consumption of these antimicrobials to treat other 
infections could explain why resistance to CLA and LVX is 
higher in older individuals, given the cumulative likelihood 
of exposure to these antimicrobials16. 
While no significant association was observed between 
antimicrobial resistant and the absence of the cagA gene, 
68% (17/25) of samples that were resistant to CLA or LVX 
were CagA-EPIYA-negative, whereas 20% (5/25) had an 
ABC genotype, considered to have low pathogenicity, and 
only 12% (3/25) carried the ABCC/ABCCC genotype9. 
Strains carrying the cagA gene develop an intense 
inflammatory response in the gastric epithelial cells and 
thus can proliferate more rapidly than cagA-negative strains. 
As antimicrobials are primarily active upon bacteria during 
the logarithmic phase of growth, cagA-positive strains are 
probably more susceptible to antimicrobial activity than 
cagA-negative strains17.
Table 1 - Profile of H. pylori-positive patients resistant and not resistant to Clarithromycin (CLA) or Levofloxacin (LVX)
Not Resistant 
(n=55)
Resistant to CLA or LVX 
(n=25) P value
Gender Female (n=41) 52.7%(29/55) 48.0% (12/25)
0.695
Male (n=39) 47.3%(26/55) 52.0% (13/25)
Age
≤ 45 years (n=34) 50.9% (28/55) 24.0% (6/25)
0.024
> 45 years (n=46) 49.1% (27/55) 76.0% (19/25)
Endoscopic Diagnostic
Normal Mucosa (n=3) 3.6% (2/55) 4.0% (1/25)
0.819Gastritis (n=54) 65.5% (36/55) 72.0% (18/25)
Gastric Ulcer (n=23) 30.9% (17/55) 24.0% (6/25)
Previous treatment 
for H. pylori
No (n=70) 89.1% (49/55) 84.0% (21/25)
0.165≤ 12 months (n=7) 5.5% (3/55) 16.0% (4/25)
> 12 months (n=3) 5.5% (3/55) 0% (0/25)
Source of water to drink
Public tap (n=68) 81.8% (45/55) 92.0% (23/25)
0.237
Mineral water (n=12) 18.2% (10/55) 8.0% (2/25)
cagA-EPIYA
No (n=50) 60.0% (33/55) 68.0% (17/25)
0.790ABC (n=19) 25.5% (14/55) 20.0% (5/25)
ABCC/ABCCC (n=11) 14.5% (8/55) 12.0% (3/25)
cagA EPIYA: cytotoxin associated gene A-Glu-Pro-Ile-Tyr-Ala
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Antimicrobial pressure can cause a loss of specific 
virulence factors (cagA) and lead to genetic rearrangements 
(loss or gain of EPIYA) that affect the impact of tyrosine 
phosphorylation, which can alter the pathogenic process 
of H. pylori in cases of treatment failure18. In this study, 
only four patients who were previously treated, presented 
therapeutic failure. Interestingly, all samples presented an 
endoscopic diagnosis of normal gastric mucosa or gastritis. 
In addition, these samples showed mutations associated with 
resistance to CLA or LVX, and 3 of 4 were cagA-negative. 
These data confirm the importance of cagA expression as a 
predictor of successful eradication, which was also reported 
by Russo et al.19.
In conclusion, in the population analyzed from the 
extreme South of Brazil, we observed high rates of 
antimicrobial resistance related to specific mutations, 
highlighting the importance of evaluating the antimicrobial 
resistance in circulating strains. Moreover, this study 
suggests a complex interplay involving the absence 
of the cagA pathogenicity marker and antimicrobial 
resistance, contributing to a deeper knowledge of 
H. pylori infection and clinical approaches for its 
treatment.
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